[Is the suicidal risk assessment scale RSD of predictive value?]

Area of Science:

• Psychiatry
• Clinical Psychology
• Epidemiology

Background:

• Many individuals who die by suicide consult a doctor within a month prior.
• Accurate assessment of suicidal risk is crucial for intervention.
• Existing methods for assessing suicidal risk factors do not always predict short-term acting out.

Purpose of the Study:

• To evaluate the clinical utility and validity of the Suicidal Risk Assessment Scale (RSD).
• To determine if the RSD can effectively predict short-term suicidal behavior.
• To compare the sensitivity of the RSD with the MADRS in assessing suicidal risk during depression treatment.

Main Methods:

• The study involved 103 patients with major depressive episodes included in a double-blind, placebo-controlled trial of fluvoxamine.
• Concurrent validity of the RSD was assessed against the MADRS and Hamilton Depression Scale.
• Predictive validity was examined through medium-term follow-up, correlating RSD scores with actual suicidal outcomes.

Main Results:

• The RSD demonstrated satisfactory concurrent validity with MADRS suicide items (rho=0.79) and Hamilton Depression Scale (rho=0.70).
• RSD showed enhanced sensitivity and faster improvement detection compared to MADRS during treatment.
• A score of 7 or higher on the RSD at inclusion predicted a significantly greater risk of suicide death (2/15 patients), while scores ≤6 indicated safety (0/88 patients).

Conclusions:

• The Suicidal Risk Assessment Scale (RSD) is a valuable clinical tool for assessing suicidal risk.
• The RSD provides a diagnostic and scientific approach to understanding the severity of suicidal intent.
• Its hierarchical structure and predictive validity make it a useful instrument for clinicians.